logo-loader
RNS
viewAdams PLC

Adams PLC - Half-year Report

RNS Number : 6521X
Adams PLC
28 November 2017
 

 

Adams plc

("Adams" or the "Company")

Interim Results for the Six Months ended 30 September 2017

 

Adams (AIM: ADA) generated a gross investment return of €24,000 in the half year ended 30 September 2017 which resulted in loss after tax of €98,000 after deduction of overheads and other costs. This compares to an investment return of €127,000 in the half year to 30 September 2016 and with a corresponding profit after tax of €24,000.

In June 2017, the Company raised cash of €1,116,000 (after expenses) pursuant to a share subscription open offer.

During the six months ended 30 September 2017, the Company spent €1,036,000 on a new equity investment in Petrofac Limited which is listed on the Main Market of the London Stock Exchange. In addition, the Company generated cash proceeds of €84,000 from the partial realisation of an existing investment.

Adams held 6 investments at 30 September 2017 comprising 5 quoted and 1 unquoted holding for which the total investment carrying value at 30 September 2017 was €2,066,000 (31 March 2017: €1,101,000 represented by 4 quoted and 1 unquoted holding).

The Company had cash balances of €89,000 at 30 September 2017, compared to cash balances of €41,000 at the previous 31 March 2017 year end.

Net assets attributable to holders of Adams at 30 September 2017 were €2,132,000 (equivalent to €0.0258 per share) versus €1,114,000 at 31 March 2017 (equivalent to €0.0270 per share). The €1,018,000 increase in net assets in the 6 months to 30 September 2017 is attributable to proceeds from the issue of shares of €1,116,000, partially offset by the loss after tax of €98,000 in the period.

Underwritten open offer and majority shareholder controlled undertaking

In order to provide the Company with additional resources with which to fund its investment strategy, the Company raised €1,116,000 (after expenses) in June 2017 pursuant to an underwritten open offer of 41,276,616 ordinary shares at 2.5p per share. Under the open offer, existing shareholders had an opportunity to subscribe for new shares at the 2.5p issue price by taking up their respective open offer entitlements which were calculated on a pro rata basis to their holding in the existing shares.

The open offer was fully underwritten by the Company's largest shareholder, Richard Griffiths who had an existing holding of 29.9 per cent in the existing shares. Following the open offer, the number of ordinary Adams shares in issue is 82,553,232 and consequent to the subscription and underwriting shares issued to Richard Griffiths, his holding increased to 63.8 per cent.

As a result, Adams is now a controlled undertaking of Richard Griffiths who will, if he so wishes, be able to further increase his interests in Adams shares without making a mandatory offer to the remaining shareholders. Subsequent to the open offer, Richard Griffiths has purchased further Adams shares in the AIM market such that his current holding in the Company is now 73.0 per cent.

The Company, Cairn Financial Advisers LLP (who are the Company's Nominated Advisor) and Richard Griffiths entered into a relationship agreement dated 2 June 2017, which governs the relationship between the Company and Richard Griffiths following the open offer, to ensure that the Company shall be managed independently for the benefit of shareholders as a whole.

Business model and change of investing policy

On 8 September 2017, shareholders approved a proposal by the Company's directors to revise the investing policy to one which provides the Board with a broader, more flexible approach to creating shareholder value. The existing policy at that time was focused on targeting undervalued or pre-commercialisation projects and assets in the biotechnology sector, whilst also considering opportunities in the wider technology and other sectors.

Under the revised investing policy, the Board will seek to acquire interests in special situation investment opportunities that have an element of distress, dislocation, dysfunction or other special situation attributes and that they perceive to be undervalued. The principal focus will be in the small to middle-market capitalisation sectors in the UK or Europe, but the directors will also consider possible special situation opportunities anywhere in the world if they believe there is an opportunity to generate added value for shareholders.

Events subsequent to 30 September 2017

On 5 October 2017, Adams sold its entire remaining holding of shares in GVC Holdings plc on the Main Market of the London Stock Exchange for a total cash consideration of £584,400.

On 16 November 2017, Adams received cash of £74,620 for its entire holding of shares in Imagination Technologies Group Plc consequent to the acquisition of that company by Canyon Bridge Capital Partners LLC under a recommended cash offer at a price of 182 pence per share.

The Adams directors intend to reinvest the proceeds of the above disposals in accordance with the Company's investing policy and on 24 November the Company used a part of the proceeds to purchase shares in Eland Oil & Gas plc on the AIM Market of the London Stock Exchange for a total cash consideration of £288,163.

Investments

The Company currently holds 4 listed investments comprising Petrofac Limited, Eland Oil & Gas plc, Oxford Pharmascience Group Plc and Communisis Plc. In addition, the Company holds shares and loan notes in unquoted Sherwood Holdings Limited, which owns Source Bioscience Plc as its principal asset.

Petrofac is a multinational service provider to the oil and gas production and processing industry. The company designs, builds, operates and maintains oil and gas facilities with a focus on delivering first class project execution, cost control and effective risk management. Petrofac has a 36-year track record and has grown significantly to become a constituent of the FTSE 250 Index. The company has 31 offices and approximately 13,500 staff worldwide, comprising more than 80 nationalities.

Eland is an independent oil and gas company with the principal business objective of identifying, acquiring and developing interests in oil and gas assets in West Africa, focused initially on Nigeria including the prolific Niger Delta.

Oxford Pharmascience is a drug development group that re-develops approved drugs to make them better, safer and easier to take. The group is currently planning to demerge its existing commercial and development assets, together with cash of around £1.3 million, into a private vehicle, and provide a continued investment in a cash shell seeking to deploy its remaining cash assets of approximately £19.3 million through the reverse acquisition of a new operating business.

Communisis is a leading provider of outsourced digital asset management and personalised customer communication services.

Source Bioscience is an international provider of state of the art laboratory services and products and has an expertise in clinical diagnostics, genomics, proteomics, drug discovery & development research and analytical testing services.

Outlook

Although the global economic cycle remains supportive of risk assets, the potential for volatility in capital markets remains. In particular, the alarming increase in China's debt and its likely slowing of economic growth and concerns about the direction of US foreign policy and trade reforms, are expected to have implications for the whole global economy. In addition, continued economic uncertainty post the Brexit vote, may impact currently reasonable Eurozone growth prospects.

The Board will, therefore, continue to maintain a highly selective investment approach in these uncertain markets.

 

Michael Bretherton

Chairman

28 November 2017

 

Enquires

 

Adams plc

 

Mike Bretherton

Tel:   +44 1534 719 761

Nomad - Cairn Financial Advisers LLP           

 

Sandy Jamieson, James Caithie

Tel:  +44 207 213 0880

Broker - Peterhouse Corporate Finance Limited

 

Lucy Williams, Duncan Vasey

Tel:  +44 207 469 0930

 


 

 

STATEMENT OF COMPREHENSIVE INCOME
 

FOR THE 6 MONTH PERIOD TO 30 SEPTEMBER 2017

 

 

 

 

6 months ended

30 Sep 2017

Year ended 31 Mar 2017

6 months ended

 30 Sep 2016

 

Note

(Unaudited)

(Audited)

(Unaudited)

 

 

€'000

€'000

€'000

 

 

 

 

 

 

 

 

 

 

Gain on investments

5

8

180

121

Dividend income

 

16

17

6

Gross investment return

 

24

197

127

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

Net foreign exchange loss

 

(36)

(15)

(15)

Administrative expenses

 

(92)

(174)

(88)

 

 

 

 

 

Operating (loss)/profit

 

(104)

8

24

Interest income

 

6

6

-

 

 

 

 

 

(Loss)/profit on ordinary activities before taxation

 

(98)

14

24

 

 

 

 

 

Tax on (loss)/profit on ordinary activities

 

-

-

-

 

 

 

 

 

(Loss)/profit for the period

 

(98)

14

24

 

 

 

 

 

Total comprehensive (loss)/income for the period

(98)

14

24

 

 

 

 

 

 

 

 

 

 

(Loss)/earnings per ordinary share

 

 

 

 

Basic and diluted

10

(0.16)€c

0.03€c

0.06€c

 

There are no other items of comprehensive income/(loss).

The accounting policies and explanatory notes set out below form an integral part of the financial statements.


 

 

STATEMENT OF FINANCIAL POSITION
 

AS AT 30 SEPTEMBER 2017

 

 

 

 

As at

30 Sep 2017

As at

31 Mar 2017

As at

30 Sep 2016

 

 

 

(Unaudited)

(Audited)

(Unaudited)

 

Note

 

€'000

€'000

€'000

Assets

 

 

 

 

 

Non-current assets

 

 

 

 

 

Investments

6

 

2,066

1,101

1,037

 

 

 

 

 

 

Current assets

 

 

 

 

 

Trade and other receivables

7

 

1

2

8

Cash and cash equivalents

 

 

89

41

96

 

 

 

90

43

104

 

 

 

 

 

 

Total assets

 

 

2,156

1,144

1,141

 

 

 

 

 

 

Liabilities

 

 

 

 

 

Current liabilities

 

 

 

 

 

Trade and other payables

8

 

(24)

(30)

(17)

Total liabilities

 

 

(24)

(30)

(17)

 

 

 

 

 

 

Net current assets

 

 

66

13

87

 

 

 

 

 

 

Net assets

 

 

2,132

1,114

1,124

 

 

 

 

 

 

Equity

 

 

 

 

 

Called up share capital

9

 

826

413

413

Share premium

9

 

1,819

1,116

1,116

Retained earnings deficit

 

 

(513)

(415)

(405)

Total shareholder equity

 

 

2,132

1,114

1,124

 

 

 

 

 

 

 

The accounting policies and explanatory notes set out below form an integral part of the financial statements.


 

 

STATEMENT OF CHANGES IN EQUITY
 

FOR THE 6 MONTH PERIOD TO 30 SEPTEMBER 2017

 

 

 

Share

Capital

Share

Premium

Retained

Earnings Deficit

Total

 

 

 

 

€'000

€'000

€'000

€'000

 

 

 

 

 

 

At 31 March 2016

 

413

1,116

(429)

1,100

 

 

 

 

 

 

Total comprehensive gain for period

 

-

-

24

24

 

 

 

 

 

 

At 30 September 2016

 

413

1,116

(405)

1,124

 

 

 

 

 

 

Total comprehensive loss for period

 

-

-

(10)

(10)

 

 

 

 

 

 

At 31 March 2017

 

413

1,116

(415)

1,114

 

 

 

 

 

 

Issue of shares

 

413

703

-

1,116

 

 

 

 

 

 

Total comprehensive loss for period

 

-

-

(98)

(98)

 

 

 

 

 

 

At 30 September 2017

 

826

1,819

(513)

2,132

 

Share capital is the amount subscribed for shares at nominal value.

Share premium represents the excess of the amount subscribed for share capital over the nominal value of these shares net of share issue expenses.

Retained earnings deficit represents the cumulative losses of the Company attributable to equity shareholders.

The accounting policies and explanatory notes set out below form an integral part of the financial statements.

 


 

 

STATEMENT OF CASH FLOWS
 

FOR THE 6 MONTH PERIOD TO 30 SEPTEMBER 2017

 

 

 

 

6 months

ended

 30 Sep 2017

Year

ended

31 Mar 2017

6 months ended

30 Sep 2016

 

(Unaudited)

(Audited)

(Unaudited)

 

€'000

€'000

€'000

 

 

 

 

(Loss)/profit for the period

(98)

14

24

Unrealised gain on revaluation of investments

(10)

(166)

(107)

Realised loss/(gain) on disposal of investments

2

(14)

(14)

Decrease/(increase) in trade and other receivables

1

1

(5)

Decrease in trade and other payables

(6)

(2)

(15)

 

 

 

 

Net cash outflows from operating activities

(111)

(167)

(117)

 

 

 

 

Cash flows from investing activities

 

 

 

Proceeds from sales of investments

84

175

65

Purchase of investments

(1,041)

(225)

(110)

 

 

 

 

Net cash used in investing activities

(957)

(50)

(45)

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

Issue of ordinary share capital

413

-

-

Issue of premium share capital, net of costs

703

-

-

 

 

 

 

Net cash generated from financing activities

1,116

-

-

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

48

(217)

(162)

 

 

 

 

Cash and cash equivalents at beginning of period

41

258

258

 

 

 

 

Cash and cash equivalents at end of period

89

41

96

 

 

 

 

 


 

 

NOTES TO THE STATEMENT OF FINANCIAL STATEMENTS
 

FOR THE 6 MONTH PERIOD TO 30 SEPTEMBER 2017

 

 

The accounting policies and explanatory notes set out below from an integral part of the financial statements.

1       General information         

Adams Plc is a company incorporated in the Isle of Man and is listed on the AIM market of the London Stock Exchange.

2       Basis of preparation

The interim financial statements of Adams Plc are unaudited condensed financial statements for the six months ended 30 September 2017. These include unaudited comparatives for the six months ended 30 September 2016 together with audited comparatives for the year ended 31 March 2017.

These interim condensed financial statements have been prepared on the basis of the accounting policies expected to apply for the financial year to 31 March 2018 which are based on the recognition and measurement principles of International Financial Reporting Standards (IFRS) as adopted by the European Union (EU). The financial statements have been prepared under the historical cost convention. The Company's presentation and functional currency is Euros.

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim Financial Reporting', and should be read in conjunction with the Company's annual financial statements to 31 March 2017. Accordingly, whilst the interim statements have been prepared in accordance with IFRS, they cannot be construed as being in full compliance with IFRS.

The preparation of financial statements in conformity with IFRS as adopted by the EU requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies.

3       Going concern       

Information on the business environment, financial position and the factors underpinning the Company's future prospects and portfolio are included in the Chairman's Statement. The Directors confirm that they are satisfied that the Company has adequate resources to continue in business for the medium term based on the current liquid resources available. For this reason, they continue to adopt the going concern basis in preparing the financial statements.

4       Significant accounting policies

The accounting policies adopted are consistent with those followed in the preparation of the annual financial statements of Adams Plc for the year ended 31 March 2017 which received an unqualified audit opinion. A copy of these financial statements are available on the website at www.adamsplc.co.uk.

 

5       Segment reporting

Operating segments for Adams Plc are reported based on the financial information provided to the Board, which is used to make strategic decisions. The Directors are of the opinion that under IFRS 8 - 'Operating segments' the Company has only one reportable segment, being Investment return. The Board assesses the performance of the operating segment based on financial information which is measured and presented in a manner consistent with that in the financial statements.

 

5       Segment reporting (continued)

The principal sources of revenue for the Company in the period to 30 September 2017 were as follows:

 

6 months ended 30 Sep 2017

Year ended 31 Mar 2017

6 months ended 30 Sep 2016

 

€'000

€'000

€'000

Unrealised gain on investments

10

166

107

Realised (loss)/gain on investments

(2)

14

14

Total gain on investments

8

180

121

 

6       Investments

An analysis of movements in the value of the Company's investments is as follows:          

 

 

Quoted Equity Shares

Unquoted Equity Shares

Unquoted Loan Notes

Total

 

€'000

€'000

€'000

€'000

Fair value at 31 March 2016

871

-

-

871

Additions at cost

7

6

97

110

Disposals

(51)

-

-

(51)

Unrealised gain on the revaluation of investments

107

-

-

107

Fair value at 30 September 2016

934

6

97

1,037

Additions at cost

102

-

13

115

Disposals

(110)

-

-

(110)

Unrealised gain on the revaluation of investments

59

-

-

59

Fair value at 31 March 2017

985

6

110

1,101

Additions at cost

1,036

-

5

1,041

Disposals

(86)

-

-

(86)

Unrealised gain/(loss) on the revaluation of investments

14

-

(4)

10

Fair value at 30 September 2017

1,949

6

111

2,066

           

     

7       Trade and other receivables

 

As at

30 Sep 2017

As at

31 Mar 2017

As at

 30 Sep 2016

 

€'000

€'000

€'000

Prepayments and accrued income

1

2

8

 

1

2

8

 

 

 

 

 

           

8       Trade and other payables

 

As at

30 Sep 2017

As at

31 Mar 2017

As at

 30 Sep 2016

 

€'000

€'000

€'000

Trade payables

10

14

12

Accruals

14

16

5

 

24

30

17

 

Accruals principally comprise amounts outstanding for ongoing expenses. The carrying amount of trade payables approximates to their fair value.

9       Share capital and share premium

Ordinary shares of €0.01

Number of shares issued and fully paid up

Share

capital

€'000

Share

premium

€'000

 

 

 

 

At 1 April 2016

41,276,616

413

1,116

 

 

 

 

Issue of shares

-

-

-

 

 

 

 

At 30 September 2016

41,276,616

413

1,116

 

 

 

 

Issue of shares

-

-

-

 

 

 

 

At 31 March 2017

41,276,616

413

1,116

 

 

 

 

Issue of shares

41,276,616

413

703

 

 

 

 

At 30 September 2017

82,553,232

826

1,819

 

In June 2017, the Company issued 41,276,616 new ordinary shares of €0.01 under an open offer at 2.5 pence (2.84 €cents) per share.

The authorised Ordinary share capital of the Company at 30 September 2017 is 350,000,000 Ordinary Shares of €0.01 each (31 March 2017 and 30 September 2016: 350,000,000 Ordinary Shares of €0.01 each).

10     Earnings/(loss) per share

The basic earnings/(loss) per share is calculated by dividing the profit/(loss) after tax attributable to equity shareholders by the weighted average number of ordinary shares in issue during the period:

 

 

6 months

ended

 30 Sep 2017

Year

ended

31 Mar 2017

6 months

ended

30 Sep 2016

 

 

 

 

Profit/(loss) after tax attributable to equity holders of the Company (€'000)

(98)

14

24

 

 

 

 

Weighted average number of ordinary shares

62,478,812

41,276,616

41,276,616

 

 

 

 

Basic and diluted earnings/(loss) per share

(0.16)€c

0.03€c

0.06€c

 

There were no potentially dilutive shares in issue as at 30 September 2017, 31 March 2017 and 30    September 2016.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR VDLFLDFFBFBB

Quick facts: Adams PLC

Price: 5.5

Market: AIM
Market Cap: £4.54 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE